The Experts below are selected from a list of 105 Experts worldwide ranked by ideXlab platform
John N Kabalin - One of the best experts on this subject based on the ideXlab platform.
-
side firing neodymium yag Laser Prostatectomy
European Urology, 1999Co-Authors: A J Costello, John N KabalinAbstract:Not until 1991 did Laser therapy for benign prostatic hyperplasia become a feasible option for the practicing urologist. Prior to the development of side firing free beam Laser delivery devices contac
-
Laser Prostatectomy performed with a right angle firing neodymium yag Laser fiber at 40 watts power setting
The Journal of Urology, 1995Co-Authors: John N KabalinAbstract:AbstractA total of 25 patients with symptomatic bladder outlet obstruction due to benign prostatic hyperplasia was entered into a prospective, randomized trial comparing Laser Prostatectomy performed with the Urolase**C. R. Bard, Inc., Covington, Georgia. right angle firing neodymium: YAG Laser fiber to standard transurethral electroresection of the prostate. Overall acute perioperative morbidity, including blood loss and fluid absorption, was significantly less for patients undergoing Laser Prostatectomy. Efficacy of treatment was assessed by standardized American Urological Association symptom scores, patient assessment of symptom improvement, peak urinary flow rates and post-void residual urine volumes, and was equivalent for the 2 treatment groups at 3 and 6 months.
-
urolase Laser Prostatectomy in patients on warfarin anticoagulation a safe treatment alternative for bladder outlet obstruction
Urology, 1993Co-Authors: John N Kabalin, Harcharan GillAbstract:Abstract Three patients with symptomatic bladder outlet obstruction due to benign prostatic hyperplasia underwent Laser Prostatectomy using a Neodymium:YAG source delivered with the Urolase right-angle Laser fiber. All patients had significant underlying medical problems, and all were fully anticoagulated with oral warfarin (mean prothrombin time 17 seconds). Two were in urinary retention with indwelling catheters preoperatively. Laser Prostatectomy was performed in each case without change in the medical regimen, including continuous warfarin dosing. No complications occurred, and in particular, no early or late bleeding episodes were encountered. All are symptomatically improved and catheter-free on follow-up. Laser Prostatectomy provides a new and safe therapeutic option in the management of these high-risk patients.
Gordon Muir - One of the best experts on this subject based on the ideXlab platform.
-
potassium titanyl phosphate Laser Prostatectomy a review
Current Opinion in Urology, 2007Co-Authors: Srinath K Chandrasekera, Gordon MuirAbstract:Purpose of reviewHigh-powered potassium titanyl phosphate Laser (GreenLight PV) has gained attention as a minimal access alternative for the treatment of prostate obstruction. This article reviews the recent data and technical refinements of potassium titanyl phosphate Laser Prostatectomy.Recent fin
David M. Barrett - One of the best experts on this subject based on the ideXlab platform.
-
high power potassium titanyl phosphate Laser vaporization Prostatectomy
Mayo Clinic Proceedings, 1998Co-Authors: Randall S Kuntzman, Reza S. Malek, David M. BarrettAbstract:In a search for potential therapeutic strategies for benign prostatic hyperplasia (BPH) that would be associated with less morbidity than transurethral resection of the prostate, various types of Laser Prostatectomy have been used. Although the neodymium: Yttrium-aluminum-garnet (Nd: YAG) Laser allows performance of Prostatectomy in an almost bloodless field and without absorption of irrigant, the remaining necrotic tissue causes bladder outlet obstruction and related symptoms for 5 to 7 days after treatment. In contrast, the potassium titanyl phosphate (KTP) Laser has been found to vaporize tissue with minimal coagulation of the underlying structures. With use of the KTP Laser, heat is concentrated into a small volume, the tissue is ablated by rapid vaporization of cellular water, and a 2-mm rim of coagulated tissue is left. After favorable results were obtained in studies of canine prostates and human cadavers, we implemented clinical use of 60-W KTP Laser Prostatectomy in selected patients. In 10 patients with symptomatic BPH who ranged in age from 52 to 80 years, outpatient KTP Laser Prostatectomy yielded significantly increased mean peak urinary flow rates (from 8.0 mL/s preoperatively to 19.4 mL/s within 24 hours after the procedure). No patient had hematuria, dysuria, or incontinence after removal of the catheter, and no patient required recatheterization. One patient, however, had urgency, and two other patients became febrile during the 24-hour observation period. Overall, KTP Laser vaporization Prostatectomy can provide immediate relief from obstructive symptoms of BPH and is not associated with dysuria.
-
high power 60 watt potassium titanyl phosphate Laser vaporization Prostatectomy in living canines and in human and canine cadavers
Urology, 1997Co-Authors: Randall S Kuntzman, Reza S. Malek, David M. Barrett, David G BostwickAbstract:Objectives We studied the safety and efficacy of 60-W potassium-titanyl-phosphate (KTP) Laser Prostatectomy in living dogs and compared the efficacy with that in fresh human and dog cadavers.
Randall S Kuntzman - One of the best experts on this subject based on the ideXlab platform.
-
high power potassium titanyl phosphate Laser vaporization Prostatectomy
Mayo Clinic Proceedings, 1998Co-Authors: Randall S Kuntzman, Reza S. Malek, David M. BarrettAbstract:In a search for potential therapeutic strategies for benign prostatic hyperplasia (BPH) that would be associated with less morbidity than transurethral resection of the prostate, various types of Laser Prostatectomy have been used. Although the neodymium: Yttrium-aluminum-garnet (Nd: YAG) Laser allows performance of Prostatectomy in an almost bloodless field and without absorption of irrigant, the remaining necrotic tissue causes bladder outlet obstruction and related symptoms for 5 to 7 days after treatment. In contrast, the potassium titanyl phosphate (KTP) Laser has been found to vaporize tissue with minimal coagulation of the underlying structures. With use of the KTP Laser, heat is concentrated into a small volume, the tissue is ablated by rapid vaporization of cellular water, and a 2-mm rim of coagulated tissue is left. After favorable results were obtained in studies of canine prostates and human cadavers, we implemented clinical use of 60-W KTP Laser Prostatectomy in selected patients. In 10 patients with symptomatic BPH who ranged in age from 52 to 80 years, outpatient KTP Laser Prostatectomy yielded significantly increased mean peak urinary flow rates (from 8.0 mL/s preoperatively to 19.4 mL/s within 24 hours after the procedure). No patient had hematuria, dysuria, or incontinence after removal of the catheter, and no patient required recatheterization. One patient, however, had urgency, and two other patients became febrile during the 24-hour observation period. Overall, KTP Laser vaporization Prostatectomy can provide immediate relief from obstructive symptoms of BPH and is not associated with dysuria.
-
high power 60 watt potassium titanyl phosphate Laser vaporization Prostatectomy in living canines and in human and canine cadavers
Urology, 1997Co-Authors: Randall S Kuntzman, Reza S. Malek, David M. Barrett, David G BostwickAbstract:Objectives We studied the safety and efficacy of 60-W potassium-titanyl-phosphate (KTP) Laser Prostatectomy in living dogs and compared the efficacy with that in fresh human and dog cadavers.
K T Foo - One of the best experts on this subject based on the ideXlab platform.
-
long term follow up of transurethral microwave thermotherapy
Urology, 1999Co-Authors: K O Lau, K T FooAbstract:Abstract Objectives. To evaluate the long-term results of transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia (BPH) with up to 5 years of follow-up at our institution. Methods. From October 1991 to November 1993, 106 patients were treated for BPH with TUMT using the Prostatron 2.0. Of the 106 patients, 64 were available for evaluation of symptoms (Madsen-Iverson score), uroflow, residual urine, and retreatment rate at a mean follow-up of 50 ± 5.4 months (mean ± SD). Results. The mean age of the patients was 65.2 ± 9.8 years. Thirty-two patients (50.0%) were treated with one session of TUMT. Additional treatments were required for 32 patients (50.0%). Three patients had two sessions of TUMT, 14 underwent transurethral resection of prostate, and 3 had Laser Prostatectomy. Twelve patients received medical therapy. The mean symptom score decreased significantly from 12.9 ± 2.5 to 5.7 ± 3.6 ( P = 0.001). The mean peak flow rates and postvoid residual volume showed little difference before and after TUMT. On the basis of the criteria described by Poincelet and Cathaud the overall clinical efficacy rate was 39.1% (15.6% complete response and 23.5% partial response). No obvious clinical parameter was useful to predict favorable outcome after TUMT. Conclusions. The present study showed that the efficacy rate of TUMT with the Prostatron 2.0 at 50 months was 39.1%. None of the preoperative clinical factors was predictive of a favorable outcome.
